1
|
Kuan Leong P, Leung HY, Man Chan W, Chen J, Zhu H, Ning J, Yang Y, Wah Ma C, Ming Ko K. An Herbal Formula (GPC) Suppresses the Releases of Pro-Inflammatory Effectors in Lipopolysaccharide/Peptidoglycan-Activated RAW264.7 Macrophages and Reduces the Extent of Chemical-Induced Acute/Chronic Inflammation in Rodents. Chin Med 2016. [DOI: 10.4236/cm.2016.74015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
2
|
Viswanatha G, Rafiq M, Thippeswamy A, Yuvaraj H, Kavya K, Baig MR, Suryakanth D, Azeemuddin M, Patki P, Pushpalatha H, Chaudhari PS, Shyam R. Ameliorative effect of Koflet formulations against pyridine-induced pharyngitis in rats. Toxicol Rep 2014; 1:293-299. [PMID: 28962246 PMCID: PMC5598515 DOI: 10.1016/j.toxrep.2014.05.003] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2014] [Revised: 04/21/2014] [Accepted: 05/08/2014] [Indexed: 11/30/2022] Open
Abstract
In present study two formulations of Koflet (syrup and lozenges) were evaluated against pyridine-induced pharyngitis in rats. Topical application of 10% pyridine showed extravasation of Evans blue stain as a characteristic feature of on-going inflammation. In addition, the levels of TNF-α (p < 0.01) and IL-6 (p < 0.01) were significantly increased compared to control. Further, histopathology of the pharyngeal tissue showed submucosal gland hypertrophy, severe mucosal inflammation characterized by presence of mononuclear cells and neutrophils along with haemorrhages and congestion; however, saline applied animals (normal control) showed normal cytoarchitecture of the pharynx. Interestingly, pre-treatment with dexamethasone (1 mg/kg, p.o.), Koflet lozenges (KL) (500 and 1000 mg/kg, p.o.) and Koflet syrup (KS) (2 and 4 ml/kg, p.o.) for 7 days showed significant and dose dependent protection by decreasing the EB dye extravasation, and serum levels of TNF-α and IL-6. In addition, histopathological findings have further supported the protective effect of Koflet formulations. These findings suggest that, both Koflet syrup and Koflet lozenges are highly effective in treating non-infectious type of pharyngitis. Among the two formulations KS was found to be more potent than KL, and possible mechanism of action thought to be mediating through inhibition of TNF-α and/or phospholipids-arachidonic acid pathway.
Collapse
Affiliation(s)
- G.L. Viswanatha
- Department of Pharmacology, R&D Center, The Himalaya Drug Company, Bangalore 562 162, India
| | - Mohamed Rafiq
- Department of Pharmacology, R&D Center, The Himalaya Drug Company, Bangalore 562 162, India
| | - A.H.M. Thippeswamy
- Department of Pharmacology, R&D Center, The Himalaya Drug Company, Bangalore 562 162, India
| | - H.C. Yuvaraj
- Department of Pharmacology, R&D Center, The Himalaya Drug Company, Bangalore 562 162, India
| | - K.J. Kavya
- Department of Pharmacology, R&D Center, The Himalaya Drug Company, Bangalore 562 162, India
| | - Mirza Rizwan Baig
- Department of Pharmacology, R&D Center, The Himalaya Drug Company, Bangalore 562 162, India
| | - D.A. Suryakanth
- Department of Pharmacology, R&D Center, The Himalaya Drug Company, Bangalore 562 162, India
| | - Mohammed Azeemuddin
- Department of Pharmacology, R&D Center, The Himalaya Drug Company, Bangalore 562 162, India
| | - P.S. Patki
- Head-Medical Services & Clinical Trials, R&D Center, The Himalaya Drug Company, Bangalore 562 162, India
| | - H.B. Pushpalatha
- Formulation & Development, R&D Center, The Himalaya Drug Company, Bangalore 562 162, India
| | - Prafulla S. Chaudhari
- Formulation & Development, R&D Center, The Himalaya Drug Company, Bangalore 562 162, India
| | - Ramakrishnan Shyam
- Chief Scientific Officer, R&D Center, The Himalaya Drug Company, Bangalore 562 162, India
| |
Collapse
|
3
|
Azeemuddin M, Viswanatha GL, Rafiq M, Thippeswamy AH, Baig MR, Kavya KJ, Patki PS, Shyam R. An improved experimental model of hemorrhoids in rats: evaluation of antihemorrhoidal activity of an herbal formulation. ISRN PHARMACOLOGY 2014; 2014:530931. [PMID: 25006493 PMCID: PMC3967498 DOI: 10.1155/2014/530931] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/12/2013] [Accepted: 02/03/2014] [Indexed: 12/12/2022]
Abstract
Objective. To improve the existing experimental model of croton oil-induced hemorrhoids in rats by using Evans Blue (EB) dye extravasation technique. Further, an herbal formulation (Pilex) was evaluated for its antihemorrhoidal activity in this model. Methods. Two sets of experiments were carried out: first to improve the experimental model and to validate the same using Pilex and second to evaluate the effect of Pilex on cytoarchitecture of rectoanal tissue in croton oil-induced hemorrhoids. In both sets, hemorrhoids were induced to all the animals, except normal controls, by applying croton oil via rectoanal region and the effect of Pilex ointment (PO), Pilex granules (PG), and combination of PG and PO was evaluated. In the first set, extravasation of EB dye, TNF- α , IL-6, and rectoanal coefficient (RAC) was determined. In the second set, severity of score, RAC, and histopathology were evaluated. Results. The elevated levels of TNF- α , IL-6, and extravasations of EB dye were decreased with the Pilex treatment. The cytoarchitecture of rectoanal portion of the animals treated with Pilex was near to normal. Conclusion. The improved experimental model of hemorrhoid is useful in quantifying the inflammatory exudates and extent of inflammation. In this improved experimental model Pilex showed antihemorrhoidal activity, which further validates its clinical usage.
Collapse
Affiliation(s)
- Mohammed Azeemuddin
- Department of Pharmacology, R&D Center, The Himalaya Drug Company, Makali, Bangalore, Karnataka 562 162, India
| | | | - Mohamed Rafiq
- Department of Pharmacology, R&D Center, The Himalaya Drug Company, Makali, Bangalore, Karnataka 562 162, India
| | - Agadi HireMath Thippeswamy
- Department of Pharmacology, R&D Center, The Himalaya Drug Company, Makali, Bangalore, Karnataka 562 162, India
| | - Mirza Rizwan Baig
- Department of Pharmacology, R&D Center, The Himalaya Drug Company, Makali, Bangalore, Karnataka 562 162, India
| | | | - Pralhad Sadashiv Patki
- Department of Pharmacology, R&D Center, The Himalaya Drug Company, Makali, Bangalore, Karnataka 562 162, India
| | - Ramakrishnan Shyam
- Department of Pharmacology, R&D Center, The Himalaya Drug Company, Makali, Bangalore, Karnataka 562 162, India
| |
Collapse
|
4
|
Viswanatha GL, Thippeswamy AHM, Rafiq M, Jagadeesh M, Baig MR, Suryakanth DA, Azeemuddin M, Patki PS, Ramakrishnan S. Novel experimental model of non-infectious pharyngitis in rats. J Pharmacol Toxicol Methods 2013; 69:189-95. [PMID: 24333504 DOI: 10.1016/j.vascn.2013.12.001] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2013] [Revised: 11/18/2013] [Accepted: 12/02/2013] [Indexed: 10/25/2022]
Abstract
INTRODUCTION Currently, there is a paucity of scientific literature and reports related to screening models for non-infectious type of pharyngitis. In this context, we made a sincere attempt to establish a novel animal model for screening drugs against non-infectious pharyngitis in rats. We have considered the use of pyridine, croton oil and their combination for inducing non-infectious pharyngitis in rats. METHODS Various concentrations of pyridine were applied topically to the pharyngeal region of rats and the extent of inflammation was assessed by Evans Blue (EB) dye exudation test, evaluating the serum levels of proinflammatory cytokines and histopathology. Dexamethasone and diclofenac were used as reference standards. RESULTS Upon pyridine application (2.5%, 5%, 10%, 20%, 40% and 80% in saline), dose-dependent increase in EB dye extravasation was observed (increased vascular permeability). In addition, the levels of TNF-α (P<0.01) and IL-6 (P<0.01) were significantly increased compared to control. Furthermore, the histopathology of pharyngeal tissue showed hypertrophy of submucosal glands, severe inflammation of the pharynx characterised by presence of mononuclear cells, neutrophils along with haemorrhages and congestion; however, normal control animals showed normal cytoarchitecture of pharynx. Indeed, dexamethasone (0.25, 0.5 and 1 mg/kg, i.v.) and diclofenac (1, 2.5 and 5 mg/kg, i.v.) showed dose-dependent protection against pyridine-induced pharyngitis. Further, the possible mechanism of pyridine-induced pharyngitis is thought to be primarily mediated through phospholipase A2 and cyclooxygenase (COX) pathway. CONCLUSION These findings suggest that pyridine-induced pharyngitis is a simple and versatile novel animal model for screening the drugs against non-infectious pharyngitis in rats.
Collapse
Affiliation(s)
- G L Viswanatha
- Department of Pharmacology, R&D Center, The Himalaya Drug Company, Bangalore, Karnataka, India.
| | - A H M Thippeswamy
- Department of Pharmacology, R&D Center, The Himalaya Drug Company, Bangalore, Karnataka, India
| | - Mohamed Rafiq
- Department of Pharmacology, R&D Center, The Himalaya Drug Company, Bangalore, Karnataka, India.
| | - M Jagadeesh
- Department of Pharmacology, R&D Center, The Himalaya Drug Company, Bangalore, Karnataka, India
| | - Mirza Rizwan Baig
- Department of Pharmacology, R&D Center, The Himalaya Drug Company, Bangalore, Karnataka, India
| | - D A Suryakanth
- Department of Pharmacology, R&D Center, The Himalaya Drug Company, Bangalore, Karnataka, India
| | - Mohammed Azeemuddin
- Department of Pharmacology, R&D Center, The Himalaya Drug Company, Bangalore, Karnataka, India
| | - P S Patki
- Department of Pharmacology, R&D Center, The Himalaya Drug Company, Bangalore, Karnataka, India
| | - Shyam Ramakrishnan
- Department of Pharmacology, R&D Center, The Himalaya Drug Company, Bangalore, Karnataka, India
| |
Collapse
|
5
|
Renner B, Mueller CA, Shephard A. Environmental and non-infectious factors in the aetiology of pharyngitis (sore throat). Inflamm Res 2012; 61:1041-52. [PMID: 22890476 PMCID: PMC3439613 DOI: 10.1007/s00011-012-0540-9] [Citation(s) in RCA: 50] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2012] [Revised: 07/22/2012] [Accepted: 07/25/2012] [Indexed: 11/17/2022] Open
Abstract
OBJECTIVES The aim of this review is to examine the causes, pathophysiology and experimental models of non-infectious pharyngitis (sore throat). INTRODUCTION The causes of sore throat can be infectious (viruses, bacteria, and fungi) or non-infectious, although the relative proportion of each is not well documented. METHODS A PubMed database search was performed for studies of non-infectious sore throat. RESULTS AND CONCLUSIONS Non-infectious causes of sore throat include: physico-chemical factors, such as smoking, snoring, shouting, tracheal intubation, medications, or concomitant illness; and environmental factors including indoor and outdoor air pollutants, temperature and humidity, and hazardous or occupational irritants. The pathophysiology underlying non-infectious sore throat is largely uncharacterised, although neurogenic inflammation looks to be a promising candidate. It is likely that there will be individual disposition factors or the coincidence of more than one irritant with possible--up to now unknown--interactions between them. Therefore, experimental models with defined conditions and objective endpoints are needed. A new model using cold dry air to directly induce pharyngeal irritation in humans, with pharyngeal lavage to measure biomarkers, may provide a useful tool for the study of mechanisms and treatment of non-infectious sore throat.
Collapse
Affiliation(s)
- Bertold Renner
- Department of Experimental and Clinical Pharmacology, University of Erlangen-Nuremberg, Krankenhausstr. 9, 91054 Erlangen, Germany.
| | | | | |
Collapse
|
6
|
Abstract
Abstract: Sodium azulene sulfonate is a water‐soluble derivative of azulene which is an antiinflammatory component of chamomile of the family of Asteraceae. Sodium azulene sulfonate is clinically used as a therapeutic agent in the treatment of pharyngitis as well as other inflammatory diseases such as tonsillitis, stomatitis and conjunctivitis. There has been no documentation on the effect of sodium azulene sulfonate on pharyngitis in laboratory models, probably because of no availability of such models. We recently established a pharyngitis model using capsaicin application on pharyngeal mucosa in rats. The present study investigated the antipharyngitis activity of sodium azulene sulfonate comparing with those of ruthenium red (vanilloid receptor antagonist, 8.5 and 85 mg/ml), ascorbic acid (antioxidative compound, 100 μg/ml), povidone iodine (gargle as disinfectant, oxidative compound, 5 and 20 mg/ml) and diclofenac sodium (cyclooxygenase inhibitor, 0.1 and 1 mg/ml). As an antipharyngeal effect, the capsaicin‐induced plasma exudation in the pharyngeal mucosa of the rat was evaluated. The capsaicin‐induced plasma exudation in the pharyngeal mucosa was inhibited by sodium azulene sulfonate (100 and 200 μg/ml) as well as ruthenium red and ascorbic acid, but not by povidone iodine and dicrofenac sodium; povidone iodine rather promoted the plasma exudation. In conclusion, the antipharyngitis effect of sodium azulene sulfonate was demonstrated for the first time in a laboratory model. Although the mechanism by which sodium azulene sulfonate inhibited the capsaicin‐induced pharyngitis is not yet unraveled, antioxidative effect, but not inhibitory effect on cyclooxygenase pathway, might be involved.
Collapse
Affiliation(s)
- Hiroyasu Sakai
- Department of Pharmacology, School of Pharmacy, Hoshi University, 2-4-41 Ebara, Shinagawa-ku, Tokyo, Japan.
| | | |
Collapse
|